CEO Jeff Jonas told BioWorld Today the regulatory path OK'd by the FDA for Sage Therapeutics Inc.'s postpartum depression (PPD) drug SAGE-547 hurries the potential availability in a severe unmet need by at least a year, and "shows the strength of the data package" brought to gatekeepers who said yes to a plan that the company had in mind all along.